To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06480552
Title An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Teva Branded Pharmaceutical Products R&D, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Teva Investigational Site 12017 RECRUITING Los Angeles California 90025 United States Details
Teva Investigational Site 12021 RECRUITING Lake Mary Florida 32746 United States Details
Teva Investigational Site 12016 RECRUITING Chicago Illinois 60611 United States Details
Teva Investigational Site 12015 RECRUITING Detroit Michigan 48201 United States Details
Teva Investigational Site 12014 RECRUITING Huntersville North Carolina 28078 United States Details
Teva Investigational Site 12058 RECRUITING Pittsburgh Pennsylvania 15232 United States Details
Teva Investigational Site 12019 RECRUITING Nashville Tennessee 37203 United States Details
Teva Investigational Site 12018 RECRUITING Fairfax Virginia 22031 United States Details
Teva Investigational Site 11282 RECRUITING Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field